UNSPSC 51272303: Nitrous oxide

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K50XQU1029. European Medicines Agency schedules Nitrous oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03447MIG. Nitrous oxide generally arises in the molecular formula N2O. The term NITROUS OXIDE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule nitrous oxide under HS 28112990 and SITC 52239.

As of Q4 2014, NITROUS OXIDE remains the US FDA Preferred Term for this commodity. Nitrous oxide bears US NLM identifiers UMLS ID C0028215 and NCI Concept Code C73617. SMILES: N#[N+][O-].

UNSPSC 51272303 Nitrous oxide is a Commodity code that encompasses pharmaceutical and medical supply procurement across state and local health systems, though recent opportunities show state and local governments using this code to solicit a broader range of health-related products including naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products rather than nitrous oxide specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). These solicitations reflect the growing role of state and local procurement in supporting community health initiatives, addiction-response programs, and cost-effective pharmacy benefit management.

Recent activity centers in Florida and across MMCAP's multistate network including Minnesota and Oregon, with exploratory procurement underway in Texas. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026, to inform future formal procurement strategy), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with multiple contract awards to manufacturers distributing through three authorized wholesalers (proposals due March 26, 2026, contracts effective July 1, 2026). MMCAP's procurement emphasizes price competitiveness (weighted at 75 percent of evaluation), cGMP and Drug Supply Chain Security Act compliance, and flexible pricing models including flat price and net-price formats.